February is American Heart Month, and consumers should be aware that a high-sodium diet can increase their risk of developing high blood pressure. An estimated one in three Americans suffer from high blood pressure, which can increase the risk of developing cardiovascular disease – the leading cause of death in men and women in the United States.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65492-u-s-fda-reduce-sodium-intake-by-using-the-nutrition-facts-label
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Unlocking the Social Potential in Autism, by Dr. Karina Poirier, is an in-depth guide to understanding autism. It empowers parents to teach their children valuable skills essential for developing friendships and achieving academic success. www.socialcognitionpublications.com
Video production by Castelane.
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Global demand for food has never been higher, as populations skyrocket and developing areas of the world strive to feed their citizens. But in the United States, more than one–third of the food produced is never eaten and a new online survey of U.S. grocery shoppers’ attitudes conducted by Harris Poll on behalf of Sealed Air Corporation (NYSE: SEE) shows that food waste in the U.S. is near the top of the list of consumers’ environmental concerns and they are willing to change behaviors if better informed on the issue. The April 2014 study interviewed over 1,000 U.S. adults (aged 18+) who do at least 25% of their household’s grocery shopping (“American grocery shoppers”).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270651-sealed-air-2014-food-waste-survey/
Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the “ecosystem” of microbes populating the intestines—linked to the development of IBD.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7204351-crohn-s-colitis-foundation-of-america-gut-bacteria-new-strategies-to-prevent/
CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, today celebrates its 25th birthday by releasing the first in a series of ‘made at CPhI’ pharma stories. These will follow 25 pharma industry successes that have directly resulted from meetings at CPhI. The first story charts Global Pharmaceutical Relief from a first meeting at CPhI only two years ago to today and providing hundreds of millions of dollars worth of medicines to the developing world via NGOs- not just another business story, but a great example of the CPhI family helping to proliferate healthcare throughout the globe.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762554-cphi-worldwide-celebrates-25-years/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Vestergaard, a global company dedicated to improving the health of disadvantaged people, launched its LifeStraw® Follow the Liters program in Kenya this month. As part of this program, high-volume LifeStraw® Community water purifiers have been distributed to provide more than 23 million liters of safe water a year to over 125,000 school children throughout Kenya’s western province.
The distribution is made possible through the LifeStraw® Follow the Liters program which harnesses the collective power of individuals to help solve one of the world’s most pressing issues – lack of access to safe drinking water for people in developing countries. When a consumer purchases any LifeStraw® product, a portion of the funds are used to provide one school child in a developing country with safe drinking water for an entire school year.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7351651-vestergaard-lifestraw-follow-the-liters-program-kenya-safe-water/
Seasoned business man Bill Foley, Hockey Vision Las Vegas and community leaders have joined together to launch a season ticket drive in support of bringing an NHL team to Las Vegas. Tickets will go on sale at www.VegasWantsHockey.com at 1:30 p.m. PST on Tuesday, Feb. 10.
“The goal of the season ticket drive is to demonstrate the long-term viability of an NHL franchise in Las Vegas, and prove that our community, without question, can support a team,” said Foley. “I think this team will not only bring Las Vegas the excitement of its first major league sports franchise, it will bring renewed enthusiasm to the Las Vegas youth – developing and impacting them in a positive way.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7424551-vegas-wants-hockey/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
